Thrombotic thrombocytopenic purpura

SummaryThrombotic thrombocytopenic purpura (TTP) is a clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytopenia and organ dysfunction due to disturbed microcirculation. TTP is characterized by a severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), an enzyme responsible for physiological cleavage of von Willebrand factor (VWF). Organ dysfunction can be severe and life-threatening, and immediate start of appropriate therapy is necessary to avoid permanent damage or death. Until recently, therapeutic options were limited to symptomatic measures, which were not standardized or based on high scientific evidence. In recent years, not only considerable progress has been made in better diagnosis of TTP, but also new therapeutic strategies have been established. Initial treatment is still based on plasma exchange and symptomatic measures to protect organ function, but new concepts (immunosuppression, targeted anti-VWF or anti-complement therapy, replacement with recombinant enzymes) have recently demonstrated impressive advantages.

• Publication year

  2018

• Venue

  Memo

• Publication date

  2018-08-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12254-018-0429-6PMID 30220931PMCID 6132833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

  2017cited by this paper
• Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

  2017cited by this paper
• Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

  2016cited by this paper
• Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.

  2016cited by this paper
• Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

  2014cited by this paper
• Treatment of refractory thrombotic thrombocytopenic purpura with N‐acetylcysteine: a case report

  2014cited by this paper
• Inherited and Acquired Thrombotic Thrombocytopenic Purpura (TTP) in Adults

  2014cited by this paper
• Treatment of thrombotic microangiopathy with a focus on new treatment options

  2013cited by this paper
• Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor

  2013cited by this paper
• Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

  2013cited by this paper
• Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry

  2013cited by this paper
• ADAMTS13 activity and genetic mutations in Japan

  2013cited by this paper
• Acquired thrombotic thrombocytopenic purpura

  2013cited by this paper
• Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes

  2013cited by this paper
• Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

  2012cited by this paper
• A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.

  2012cited by this paper
• Autoimmune Thrombotic Microangiopathy: Advances in Pathogenesis, Diagnosis, and Management

  2012cited by this paper
• Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome, 1996 to 2011 (CME)

  2012cited by this paper
• Inverse correlation of free and immune complex‐sequestered anti‐ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura

  2012cited by this paper
• Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience

  2012cited by this paper
• Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

  2012cited by this paper
• Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13

  2012cited by this paper
• N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.

  2011cited by this paper
• Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan

  2011cited by this paper
• Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw–Schulman syndrome

  2011cited by this paper
• Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura

  2011cited by this paper
• A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

  2011cited by this paper
• Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13)

  2008cited by this paper
• Thrombotic thrombocytopenic purpura.

  2005cited by this paper
• Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.

  2003cited by this paper
• von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

  1998cited by this paper
• Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

  1998cited by this paper
• Clinical applications of N-acetylcysteine.

  1998cited by this paper
• Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma‐exchange

  1994cited by this paper
• Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

  1991cited by this paper
• Treatment of thrombotic thrombocytopenic purpura

  1983cited by this paper
• Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.

  1982cited by this paper

• Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis

  2024cites this paper
• Concurrent myocardial infarction in the setting of thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus: A case report

  2024cites this paper
• Schistocyte detection in artificial intelligence age

  2024cites this paper
• Assessing Biomarkers in Viral Infection.

  2023cites this paper
• Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia

  2023cites this paper
• Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study

  2022cites this paper
• Case Report: Systemic lupus erythematous associated with thrombotic thrombocytopenic purpura, a diagnostic challenge

  2022cites this paper
• HIV‐associated thrombotic thrombocytopenic purpura (HIV‐TTP): A practical guide and review of the literature

  2022cites this paper
• THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER VACCINATION AGAINST COVID-19 – A CASE REPORT

  2022cites this paper
• New missense mutation p.Trp387Ser affecting the functionally important TrpXXTrp motif in the TSR1 repeat of ADAMTS13 metalloproteinase: Case report

  2022cites this paper
• Concurrent thrombotic thrombocytopenic purpura and Guillian Barre Syndrome post infectious diarrhea

  2022cites this paper
• Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura: A case report

  2022cites this paper
• Self-limited thrombotic thrombocytopenic purpura

  2022cites this paper
• Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review

  2022cites this paper
• Hypertensive Emergency as the Initial Presentation of Acquired Thrombotic Thrombocytopenic Purpura: A Case Report

  2021cites this paper
• An Imperfect Marker: SLE and TTP-Like MAHA Without Low ADAMTS13

  2021cites this paper
• Parvovirus Infection and Thrombotic Thrombocytopenic Purpura in an Adult Patient With Sickle Cell Beta-Thalassemia

  2021cites this paper
• [Treatment of thrombotic thrombocytopenic purpura].

  2021cites this paper
• [Treatment of thrombotic thrombocytopenic purpura].

  2021cites this paper
• Hautveränderungen bei Kindern und Erwachsenen

  2020cites this paper
• Case of acquired thrombotic thrombocytopenic purpura associated with influenza A (H1N1) virus and literature review

  2020cites this paper
• Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

  2019cites this paper
• Atypische intrazerebrale Blutungen – Ätiologie und Akutmanagement

  2019cites this paper
• Caplacizumab – eine neue Begleittherapie der TTP

  2018cites this paper